By PPN News Staff
The FDA approved adalimumab-afzb (Abrilada, Pfizer), the fifth biosimilar to adalimumab (Humira, AbbVie) for the treatment of certain patients with rheumatoid arthritis (RA), juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, ulcerative colitis and plaque psoriasis.
The FDA approval was based on the review of a comprehensive data package, which demonstrated biosimilarity of adalimumab-afzb to the reference product. This